XNAS · Healthcare · Biotechnology
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 1.64 | 1.63 | -0.61% | $51.7M | ❌ Miss | -1.48% | +4.11% | — |
| 2026-02-26 | Q4 2025 | 1.15 | 2.02 | +75.65% | $59.7M | ✅ Beat | +0.06% | +5.15% | -0.35% |
| 2025-11-06 |
| Q3 2025 |
| 1.57 |
| 3.09 |
| +96.82% |
| $115.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 0.94 | 1.60 | +70.21% | $47.6M | ✅ Beat | +1.69% | +5.11% | +13.96% |
| 2025-02-27 | Q4 2024 | 1.19 | 1.27 | +6.72% | $42.8M | ✅ Beat | +5.67% | +0.29% | -9.10% |
| 2024-11-07 | Q3 2024 | 1.35 | 1.84 | +36.30% | $51.8M | ✅ Beat | -6.66% | -11.12% | -10.44% |
| 2024-08-06 | Q2 2024 | 0.98 | 1.40 | +42.86% | $41.5M | ✅ Beat | -5.78% | +4.02% | +4.15% |
| 2024-05-07 | Q1 2024 | 0.78 | 3.84 | +392.31% | $31.0M | ✅ Beat | +9.75% | +16.48% | +12.50% |
Showing last 8 quarters.